Clinical Trial Update: Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC) [Phase 2, Phase 3]

View source ↗

Summary

Trial update comparing pulsatile high-dose sunitinib to TAS-102 in metastatic colorectal cancer (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Sunitinib (sunitinib)
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Colorectal Cancer, Metastasis | Phase 2, Phase 3 | Status: UNKNOWN